Payment overview · 2025
General Payments
$650.24
32 reported records · 16 companies
Healthcare provider profile · identity verified
Subashini Narayanan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FRISCO, TX · NPI 1710986864
Verified facts
What the public records show
CMS Open Payments records show Subashini Narayanan, MD received $650.24 in general payments during 2025 across 32 reported records.
Abbott Laboratories accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $131.47 | 20.2% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $88.85 | 13.7% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $69.36 | 10.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.12 | 7.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.87 | 7.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.50 | 5.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.89 | 5.5% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $34.54 | 5.3% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $22.94 | 3.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.61 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.72 | 3.3% | 1 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $20.78 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.69 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.37 | 2.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.76 | 2.7% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.77 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $650.24 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $111.01 | 6 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $69.36 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.26 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.88 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.87 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.50 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.89 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $34.54 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.81 | 2 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.72 | 1 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $20.78 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.59 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $20.46 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 179 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 161 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 144 | 43 |
| Montelukast Sodium | Montelukast Sodium | 84 | 35 |
| Losartan Potassium | Losartan Potassium | 71 | 23 |
| Lisinopril | Lisinopril | 67 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 12 |
| Gabapentin | Gabapentin | 61 | 24 |
| Metformin Hcl | Metformin Hcl | 59 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 54 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 49 | 12 |
| Trazodone Hcl | Trazodone Hcl | 47 | 14 |
| Meloxicam | Meloxicam | 46 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | 15 |
| Omeprazole | Omeprazole | 45 | 17 |
| Simvastatin | Simvastatin | 45 | 12 |
| Temazepam | Temazepam | 35 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 34 | 16 |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Prednisone | Prednisone | 33 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 12 |
| Pantoprazole Sodium | Pantoprazole Sodium | 30 | 11 |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 30 | 11 |
| Tramadol Hcl | Tramadol Hcl | 30 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 22 |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Azithromycin | Azithromycin | 22 | 18 |
| Lorazepam | Lorazepam | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Potassium Chloride | Potassium Chloride | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 18 | suppressed |
| Furosemide | Furosemide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Alprazolam | Alprazolam | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 12 |
| Allopurinol | Allopurinol | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $650.24 · 32 records | Abbott Laboratories | AIRSUPRA, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, Fluad, Flucelvax, INCEPTIV, INGREZZA, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JARDIANCE, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, PROCLAIM, Prospera, The Cologuard Plus Collection Kit, UBRELVY, Veozah, WaveWriter Alpha Prime 16, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error